New HIV PrEP Drug Not Cost-Effective Compared With Generic
F/TAF would avert 2,101 fractures, 25 cases of end-stage renal disease, but not deemed cost-effective
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.